Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, NuProbe Partner on Rare Variant Enrichment in Liquid Biopsy Tests

NEW YORK – NuProbe and Qiagen have entered into a strategic collaboration to develop next-generation sequencing-based cancer liquid biopsy tests, the firms announced Monday.

Under the terms of their agreement, NuProbe and Qiagen will explore integration of their amplicon-based target enrichment technologies — NuProbe's blocker displacement amplification (BDA) and Qiagen's single primer extension technology — to analyze DNA mutations with low variant allele fractions.

The partners will initially develop a research-use only product for clinical oncology, but said in a statement they "may explore further strategic collaboration and develop other commercial products."

Financial and other terms of the agreement were not disclosed.

"We are excited about the potential products that will come out of the two synergistic rare variant enrichment and detection methods," Yingshuang Chai, NuProbe CEO and chairman, said in a statement. "This collaboration further demonstrates the adoption of our cutting-edge technology by industry leaders."

The deal is the third partnership this year for NuProbe, a Wyss Institute spinout that completed a merger with China's CarrierGene Biotech earlier this year. In January, the company announced a partnership with Illumina to offer target enrichment assays and in February Oxford Nanopore Technologies licensed NuProbe's BDA tech to help expand into cancer research. 

Qiagen's business relationships have recently been in flux. In October 2019, the firm announced that it would discontinue development of its GeneReader sequencing platform and would partner with Illumina to develop diagnostic panels. Earlier this month, Thermo Fisher Scientific said it would buy Qiagen for $11.5 billion in cash.

Last week, Natera terminated its license, development, and distribution agreement with Qiagen, citing the Illumina deal.

NuProbe also announced it has submitted five CE-IVD registrations for products including liquid biopsy tests for EGFR and BRAF gene mutations. NuProbe plans on obtaining CE-IVD and China National Medical Products Administration registration for additional products, the firm said.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.